CDEK
← All organizations

Revance Therapeutics, Inc.

For profitContributed to NMEWebsite ↗

Also known as: Revance Therapeutics, Inc. | REVANCE THERAPEUTICS, INC.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Nov 1, 2008

First marketed drug

Sep 7, 2022

First NDA

Sep 7, 2022

Last known activity

Nov 30, 2024

Acquired by Crown Laboratories, Inc. on Aug 13, 2024

Timeline

1990s

  1. Jan 1, 1999

    Revance Therapeutics, Inc.— Founded

2020s

  1. Sep 7, 2022

    daxibotulinumtoxinA— Marketing Organization

  2. Sep 7, 2022

    daxibotulinumtoxinA— NDA Organization

  3. Sep 7, 2022

    daxibotulinumtoxinA— NDA Secondary Org

  4. Aug 13, 2024

    Crown Laboratories, Inc.— Acquired By

Drugs by trial phase (3 distinct, 28 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 3 (1 own, 0 via acquisition)

Phase 2 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Recent trials (33)

Details

Founded
Newark, CA, US Jan 1, 1999
First NDA
Sep 7, 2022
Last known activity
Nov 30, 2024

Designations held

  • Orphan drug